Northway Biotech
16.5.2023 14:32:41 CEST | ACCESS Newswire | Press release
KIEL, GERMANY / ACCESSWIRE / May 16, 2023 / tiakis Biotech AG (tiakis), in collaboration with its CDMO partner Northway Biotech, is pleased to announce the successful completion of a technology transfer and ramp-up of manufacturing capabilities for Tiprelestat, a pioneering anti-inflammatory and tissue-protective drug being developed for the prevention of postoperative inflammatory complications following major surgery, treatment of COVID-19 and pulmonary arterial hypertension. For the first time worldwide, a clinical trial is being supported by Tiprelestat study material produced at an industrial fermentation scale, representing a ten-fold increase in manufacturing potential to 3,000 L.
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.tiakis Biotech AG and Northway Biotech: Successful Tech Transfer and Expansion of Manufacturing Capabilities for Tiprelestat
"The marked increase in manufacturing capabilities lays the foundation for the next stage of tiakis' development programs, with the recent start of our COMCOVID phase Ib/II clinical trial being a prime example," said Martin Voss, tiakis Biotech AG co-CEO.
The enhanced production capabilities is a result of the successful completion of a technology transfer and subsequent ramp-up program, achieved in a short time through close collaboration with end-to-end biologics CDMO Northway Biotech, based in Vilnius, Lithuania.
Reflecting on this milestone, Vladas Algirdas Bumelis, CEO of Northway Biotech, stated: "The confidence our partners have placed in our two-decade-long expertise has enabled us to collaboratively scale up the process and meet tiakis' deadlines. Our state-of-the-art 3,000 L stainless-steel fermenter train was utilized to carry out the implementation successfully. We extend our sincere well-wishes to our partners as they move forward with their innovative drug through clinical trials, and we look forward to future collaborations."
André Markmann, VP Business Development of Northway Biotech, added: "This partnership exemplifies our commitment to assist our partners in achieving their objectives by leveraging our technical expertise and operational capabilities. We are immensely proud to be part of this groundbreaking project, which addresses a significant unmet medical need."
By attaining this pharmaceutical and technological milestone, tiakis and Northway Biotech have demonstrated their capabilities to pave the way towards groundbreaking achievements as pioneers in their respective fields. The success of this fast-paced project is characterized by strong collaborative interaction, mutual trust, and flexibility between the two companies.
About Tiprelestat
tiakis biopharmaceutical drug candidate Tiprelestat promises an excellent therapeutic benefit-risk profile for use as an anti-inflammatory and tissue-protective drug. Tiprelestat is identical to the human protein elafin with high specificity for tissue-destroying and inflammation-promoting proteases. The development program of Tiprelestat is focused on the late-stage development of Tiprelestat in major surgery and early-stage development in pulmonary arterial hypertension (PAH) and COVID-19.
About tiakis Biotech AG
tiakis focuses on the discovery and development of therapeutic solutions based on its innovative biopharmaceutical Tiprelestat for life-threatening surgeries and life-threatening diseases such as PAH and COVID-19. tiakis seeks partners and investors for the development, commercial-scale manufacturing, marketing and distribution of the product. The company tiakis Biotech AG is located in Kiel, Germany (www.tiakis.bio).
About Northway Biotech
Northway Biotech is a leading contract development and manufacturing organization (CDMO) supporting customers worldwide. Its highly experienced, professional team executes projects at any stage, from cell line construction and process development to cGMP manufacturing of biopharmaceutical products. The company's wide-ranging expertise and vertically integrated service offering translate to the ability to rapidly execute multiple projects from its state-of-the-art GMP facilities while ensuring full process and product compliance at all stages of research, development and commercial manufacturing. Northway Biotech is a privately owned company founded in 2004 and located in Vilnius, Lithuania, London, United Kingdom, and in Waltham, MA, US. Further information can be found on Northway's website www.northwaybiotech.com.
Contact Information
Vladas Bumelis
CEO and Chairman of the Board
vladas.bumelis@northwaybiotech.com
SOURCE: Northway Biotech
To view this piece of content from stats.newswire.com, please give your consent at the top of this page.View source version on accesswire.com:
https://www.accesswire.com/755218/tiakis-Biotech-AG-and-Northway-Biotech-Successful-Tech-Transfer-and-Expansion-of-Manufacturing-Capabilities-for-Tiprelestat
To view this piece of content from www.accesswire.com, please give your consent at the top of this page.
About ACCESS Newswire
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Karbon-X Named Official Sustainability Partner of the Detroit Red Wings and Detroit Tigers1.4.2026 15:00:00 CEST | Press release
Multi-year partnership introduces verified environmental reporting and new fan-driven climate action across Little Caesars Arena and Comerica Park. CALGARY, AB / ACCESS Newswire / April 1, 2026 / Karbon-X Corp. (OTCQX:KARX) ("Karbon-X" or "the Company") today announced a multi-year sustainability partnership with the Detroit Red Wings and Detroit Tigers, establishing Karbon-X as the Official Sustainability Partner across both teams through Ilitch Sports + Entertainment. The collaboration brings verified climate action to two of Detroit's most celebrated franchises, supporting long-term environmental strategy at Little Caesars Arena and Comerica Park, and introducing new ways for fans to participate in meaningful sustainability efforts. As part of the partnership, Karbon-X will deliver independent, third-party greenhouse gas reporting for both organizations. These insights will support future planning and help identify opportunities to strengthen environmental performance across venue o
Datavault AI Returns a Second Time for Exclusive Investor Forum at Mar-a-Lago1.4.2026 14:00:00 CEST | Press release
Private Round Table Follows Tech Summit Appearance in Utah for International Lawyers, Addressing Advancements in AI PHILADELPHIA, PA / ACCESS Newswire / April 1, 2026 / Datavault AI Inc. (NASDAQ:DVLT) CEO Nate Bradley will present at a private investor round table on Thursday, April 02, 2026, at The Mar-a-Lago Club in Palm Beach, Florida, marking his second invitation to the venue in two months following a strong institutional reception in February. The invitation follows presentations Bradley delivered earlier this week to leading global attorneys on AI applications in legal practice and data governance. The return engagement comes amid growing institutional interest in Datavault AI's approach to data monetization, verified credentialing, and real-world asset tokenization. It reflects growing market recognition of Datavault AI's differentiated position at the intersection of data ownership, tokenization, and AI-enabled revenue generation. The April round table builds on momentum from
Jenny Hammarberg Appointed CEO of Lawline - Bringing Legal Expertise to Users Through AI1.4.2026 13:15:00 CEST | Press release
Lawline has appointed Jenny Hammarberg as its new Chief Executive Officer. She joins from her previous role as CEO of Setterwalls Advokatbyrå in Gothenburg and has previous experience as a management consultant at EY. She takes on the role at a pivotal moment as Lawline launches its new platform for businesses, organisations, and private individuals. STOCKHOLM, SE / ACCESS Newswire / April 1, 2026 / Lawline, the market leader for accessible law online since 2005, has set its sights on transforming how legal services are accessed and used. Rather than legal advice being purchased reactively after the fact, the vision is for legal guidance to be available at the moment of decision. "I have seen too many situations where legal counsel arrives when it is already too late - where a simple answer could have saved money, unnecessary frustration, and energy. Legal support should not be something you activate when things are already on fire." - Jenny Hammarberg, CEO, Lawline Lawline is position
Datavault AI and Coppercore Inc. Announce Tokenization of High-Grade Copper Resources into Coppercoin(TM)31.3.2026 15:15:00 CEST | Press release
$100 Million in Initial Coppercoin™ Issuance to Set Industry Standard in Tokenized Copper PHILADELPHIA, PA / ACCESS Newswire / March 31, 2026 / Datavault AI Inc. ("Datavault AI" or the "Company") (NASDAQ:DVLT), a leader in data monetization, credentialing, digital engagement, and real-world asset (RWA) tokenization technologies, and Coppercore Inc. ("Coppercore") today announced the closing of a definitive agreement to digitize and tokenize significant copper resources. The transaction enables Datavault AI to deploy its patented IDE®, DataScore®, and DataValue® blockchain tokenization platform to create Coppercoin™ digital tokens representing pro-rata ownership interests in the underlying in-ground resources. The initial program targets the minting of $100 million or more in Digital Copper Tokens. Coppercoin™ tokens are structured such that each token corresponds to five pounds of underlying high-grade copper resources, with pricing directly linked to the COMEX copper benchmark on a pe
AccessPay Accelerates Growth With Majority Investment From Leading Software Investor, Accel-KKR31.3.2026 10:00:00 CEST | Press release
Financial backing enables AccessPay to scale services for enterprise clients and drive innovation in finance operations MANCHESTER, UK / ACCESS Newswire / March 31, 2026 / AccessPay, a leading bank integration and payment automation provider, has secured a majority investment from Accel-KKR, a prominent global private equity firm specialising in enterprise technology and software companies. The investment is expected to enable AccessPay to fuel the next phase of growth and further its ambition to become a world-class SaaS business driving innovation in the office of the CFO. The investment also opens the door for AccessPay to pursue growth via strategic acquisitions. The office of the CFO faces an increasingly testing operating environment. Alongside cost pressures, increased cyber threats, and a volatile geopolitical climate, AI is fundamentally rewiring finance operating practices. A global McKinsey survey of CFOs from late 2025 reported that 44% of survey respondents had identified
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom